Skip to main content
SpringerLink
Log in

Pharmacokinetics of a New Once-Daily Controlled-Release Formulation of Aceclofenac in Korean Healthy Subjects Compared with Immediate-Release Aceclofenac and the Effect of Food

A Randomized, Open-Label, Three-Period, Crossover, Single-Centre Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background: A new controlled-release formulation of aceclofenac 200 mg (Clanza CR®) developed by Korea United Pharm., Inc., South Korea, for once-daily (od) dosing provides biphasic aceclofenac release consisting of immediate release of 85 mg followed by sustained release of 115 mg. Food has been known to affect the rate and extent of absorption of several drugs, in both immediate-release and controlled-release formulations.

Objective: The aim of this study was to evaluate the relative bioavailability of a new controlled-release formulation of aceclofenac (200 mg od; Clanza CR®) in comparison with immediate-release aceclofenac (100 mg twice daily [bid], Airtal®) and to assess the effect of food on the pharmacokinetics of the new controlled-release aceclofenac formulation.

Methods: This study was designed as a randomized, open-label, three treatment-period, crossover, single-centre study with a 1-week washout in 41 healthy adults. The three treatments consisted of immediate-release aceclofenac 100 mg bid administered under fasting conditions; controlled-release aceclofenac 200 mg od administered under fasting conditions; and controlled-release aceclofenac 200 mg od administered immediately after a standardized high-fat breakfast. Plasma concentrations of aceclofenac were determined using a highperformance liquid chromatography method.

Results: In the fasted state, the 90% confidence intervals (CIs) of the least squares geometric mean ratios (GMRs) for the area under the plasma concentration-time curve from time zero to 24 hours (AUC24) and the peak plasma concentration (Cmax) of aceclofenac for the controlled-release and immediate-release formulations of aceclofenac were all within the bioequivalence criteria range of 0.8–1.25. The 90% CIs of the GMRs for the AUC24 and Cmax of aceclofenac for the controlled-release formulation of aceclofenac in the fed and fasted states were also within the bioequivalence range. Both aceclofenac formulations were well tolerated in all subjects, and no serious adverse effects were observed.

Conclusion: The results demonstrate that controlled-release aceclofenac 200 mg is equivalent to immediate-release aceclofenac 100 mg when administered at the same total daily dose. Additionally, the bioavailability of controlled-release aceclofenac was not affected by high-fat foods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II

Similar content being viewed by others

References

  1. Brogden RN, Wiseman LR. Aceclofenac: a review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996; 52: 113–24

    Article  PubMed  CAS  Google Scholar 

  2. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61: 1351–78

    Article  PubMed  CAS  Google Scholar 

  3. Grau M, Guasch J, Montero JL, et al. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneimittelforschung 1991; 41: 1265–76

    PubMed  CAS  Google Scholar 

  4. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004; 5: 1347–57

    Article  PubMed  CAS  Google Scholar 

  5. Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996; 23: 1200–6

    PubMed  CAS  Google Scholar 

  6. Kornasoff D, Maisenbacher J, Bowdler J, et al. The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol Int 1996; 15: 225–30

    Article  PubMed  CAS  Google Scholar 

  7. Llorente Melero MJ, Ten;ias Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig 2002; 94: 7–18

    PubMed  CAS  Google Scholar 

  8. Pasero G, Marcolongo R, Serni U, et al. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr Med Res Opin 1995; 13: 305–15

    Article  PubMed  CAS  Google Scholar 

  9. Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 1996; 15: 473–7

    Article  PubMed  CAS  Google Scholar 

  10. Kim YG, Lee YJ, Kim HJ, et al. Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers. Int J Clin Pharmacol Ther 2001; 39: 83–8

    PubMed  CAS  Google Scholar 

  11. Najib N, Idkaidek N, Beshtawi M, et al. Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. Biopharm Drug Dispos 2004; 25: 103–8

    Article  PubMed  CAS  Google Scholar 

  12. Rhim SY, Park JH, Park YS, et al. Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. Clin Ther 2008; 30: 633–40

    Article  PubMed  CAS  Google Scholar 

  13. Yong CS, Oh YK, Lee KH, et al. Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects. Int J Pharm 2005; 302: 78–83

    Article  PubMed  CAS  Google Scholar 

  14. Bort R, Ponsoda X, Carrasco E, et al. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24: 834–41

    PubMed  CAS  Google Scholar 

  15. Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999; 289: 676–81

    PubMed  CAS  Google Scholar 

  16. Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000; 49: 133–8

    Article  PubMed  CAS  Google Scholar 

  17. Mutalik S, Manoj K, Reddy MS, et al. Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: in vitro and in vivo studies. AAPS PharmSciTech 2008; 9: 651–9

    Article  PubMed  CAS  Google Scholar 

  18. Mutalik S, Naha A, Usha AN, et al. Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac. Arch Pharm Res 2007; 30: 222–34

    Article  PubMed  CAS  Google Scholar 

  19. Pareek A, Chandurkar N, Gupta A, et al. Efficacy and safety of aceclofenac-CR and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain 2011; 12: 546–53

    PubMed  CAS  Google Scholar 

  20. Boullata JI, Armenti VT. Food effects on modified-release formulations. In: Boullata JI, Armenti VT, editors. Handbook of drug-nutrient interactions, 2nd ed. Totowa (NJ): Humana Press, 2010: 227–33

    Chapter  Google Scholar 

  21. Kang W, Kim EY. Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2008; 46: 587–91

    Article  PubMed  CAS  Google Scholar 

  22. Hermann M, Christensen H, Reubsaet JLE. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 2005; 382: 1242–9

    Article  PubMed  CAS  Google Scholar 

  23. Food and Drug Administration. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002

  24. European Agency for the Evaluation of Medicinal Products. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). London: Human Medicines Evaluation Unit, 1999

    Google Scholar 

  25. Movilia PG. Evaluation of the analgesic activity and tolerability of aceclofenac in the treatment of post-episiotomy pain. Drugs Exp Clin Res 1989; 15: 47–51

    PubMed  CAS  Google Scholar 

  26. Yscla A. Aceclofenac and paracetamol in episiotomal pain. Drugs Exp Clin Res 1988; 14: 491–4

    PubMed  CAS  Google Scholar 

  27. Honorato J, Caballero R, Giorgianni G, et al. Doseanalgesic response study and aceclofenac plasma levels in humans. Curr Ther Res Clin Exp 1990; 40: 605–11

    Google Scholar 

  28. Cecchettin M, Cerea P, Torri G. Therapeutic efficacy of aceclofenac and diclofenac in acute knee arthroses: a study of E2-prostaglandin levels in synovial fluid and in serum. Clin Trials J 1988; 25: 144–51

    Google Scholar 

Download references

Acknowledgements

Drs Soo Kyung Bae and Soo-Hwan Kim contributed equally to this study. The study was supported by Korea United Pharm., Inc., Seoul, South Korea. The authors do not have a commercial or any other association that might pose a conflict of interest.

Author information

Authors and Affiliations

  1. College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea

    Soo Kyung Bae

  2. Hopkins Bio Research Center, Inc., 107 Yangjae-dong 4th Fl., Seocho-gu, Seoul, 137-891, South Korea

    Soo-Hwan Kim, Su-Yeon Shin, Sang Hun Lee &  Hye Jung Lee

  3. Department of Biomedical Science and Clinical Trial Center, Kyungpook National University Graduate School and Hospital, 200 Dongduk-ro, Jung-gu, Daegu, 700-721, South Korea

    Hae Won Lee, Sook Jin Seong, Mi-Sun Lim &  Young-Ran Yoon

Authors
  1. Soo Kyung Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soo-Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hae Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sook Jin Seong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Su-Yeon Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sang Hun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mi-Sun Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Young-Ran Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hye Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Young-Ran Yoon or Hye Jung Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bae, S.K., Kim, SH., Lee, H.W. et al. Pharmacokinetics of a New Once-Daily Controlled-Release Formulation of Aceclofenac in Korean Healthy Subjects Compared with Immediate-Release Aceclofenac and the Effect of Food. Clin Drug Investig 32, 111–119 (2012). https://doi.org/10.2165/11596530-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11596530-000000000-00000

Keywords

Search

Navigation